2023-503683-16-00CompletedPhase 1
A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jan 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 7 Jun 2023
- Start date
- 16 Oct 2023
- Lead sponsor
- Breye Therapeutics ApS
- Diseases
- Diabetic eye disease
- EU CT number
- 2023-503683-16-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 3
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (4)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR | Berlin | Germany | Completed |
| Universitaetsklinikum Bonn AöR | Bonn | Germany | Completed |
| Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR | Mainz | Germany | Completed |
| Universitaetsklinikum Tuebingen AöR | Tuebingen | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.